‘The Neuroscience of Addiction Recovery’
Dr. Montoya is the Director of the Division of Therapeutics and MedicalConsequences (DTMC) of NIDA. He has a Medical Doctor and Psychiatrist degree from the University of Antioquia in Colombia and a Master’s in Public Health from Johns Hopkins University. He was a Humphrey Fellow at Johns Hopkins and a Visiting Fellow at the Intramural Research Program of NIDA. He joined NIDA’s extramural program in 1999 as a Medical Officer of the ClinicalTrials Network, became the Deputy Director of DTMC in 2008 and the Director of DTMC in 2024. He has participated in the development of multiple medications for Substance Use Disorders (SUD) that have received FDA approval, including buprenorphine, probuphine®, depot naltrexone, lofexidine, intranasal naloxone, intranasal nalmefene, etc. He has published extensively about treatments (pharmacological and non-pharmacological), as well as the medical consequences of SUDs. He has received multiple awards, including the NIH Director’s and Michael Morrison awards from CPDD. He is also an Honorary Professor at the University of Valencia (Spain).